Patent Term Extension Application for BLUJEPA (gepotidacin mesylate), Patent No. 8,389,524 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-2426

Patent Term Extension Application for BLUJEPA (gepotidacin mesylate), Patent No. 8,389,524

Documents

Comments

Description

OPEN

Comment Period OpensJul 16, 2025

Comment Period ClosesAug 13, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA FR Doc: 2026-02901	Feb 13, 2026	--

CDER

Patent Term Extension Application

GlaxoSmithKline

Glaxo Group Limited

BLUJEPA (gepotidacin mesylate)

Patent No. 8,389,524

OPEN